Zhejiang Hengkang Salcaprozate Sodium Zhejiang Hengkang Salcaprozate Sodium

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Ottawa Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Salcaprozate Sodium

    Menu

    Salcaprozate Sodium

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    MARKET PLACE

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Intensity Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements

              Details:

              The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer.

              Lead Product(s): Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium

              Therapeutic Area: Oncology Product Name: INT230-6

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ottawa Hospital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma Salcaprozate Sodium
              AMI Salcaprozate Sodium
              Close
              4
              Post Enquiry
              POST ENQUIRY